Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Dr Reddys unveils...

    Dr Reddys unveils generic version of Zyban ER tablets in US

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-09-05T17:01:01+05:30  |  Updated On 17 Aug 2021 12:29 PM IST

    The company has launched Bupropion hydrochloride extended-release tablets USP (SR), approved by the United States Food and Drug Administration (USFDA), Dr Reddys said in a filing to BSE.


    New Delhi: Dr Reddy's Laboratories on Thursday said it has launched in the US generic Bupropion hydrochloride extended-release tablets indicated as an aid to smoking cessation treatment.


    The company has launched Bupropion hydrochloride extended-release tablets USP (SR), approved by the United States Food and Drug Administration (USFDA), the drug firm said in a filing to BSE.


    Read Also: Dr Reddys gets 8 USFDA observations for Duvvada facility in Andhra Pradesh


    The product is a generic version of GSK group of companies' Zyban extended-release tablets, it added.


    According to IQVIA Health, the Zyban brand and generic had US sales of around USD 5.4 million MAT for the 12 months ended June 2019, the company said.


    Dr Reddy's tablets are available as 150 mg dosage strength in bottle count sizes of 60, it added.


    Read Also: Dr Reddy's launches generic version of Sabril powder in US to treat epilepsy

    BSEBupropionBupropion HydrochlorideDr ReddyDr Reddy'sDr Reddy's LaboratoriesDr Reddy's Labsdr reddys launchGSKIQVIA Healthpharmapharma companypharma newspharma news indiaUnited States Food and Drug AdministrationUSFDAUSFDA approvalUSFDA nodZybanZyban ER tablets
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok